Share Issue/Capital Change • Mar 18, 2015
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Malakoff, FRANCE – March 18, 2015 – THERACLION (Alternext, FR0010120402 - ALTHE), a company specializing in leading-edge medical equipment for echotherapy, today announces the arrangement of an equity line financing with Kepler Cheuvreux.
Pursuant to this arrangement, and subject to the conditions defined by the two parties being met, Kepler Cheuvreux has committed to subscribe to successive capital increases, issued by tranches over the next 36 months, within the global limit of 400,000 new Theraclion shares, or 10.6% of the Company's current share capital, that could allow Theraclion to receive €4.3 million[1] in equity at the current stock price. Theraclion retains control of the pace of the financial support provided by Kepler Cheuvreux, and can hold the contract at any time.
The issuance price of the new Theraclion shares will reflect the share market price at the time of issuance, minus a maximum 7.5% discount. The discount allows Kepler Cheuvreux to act as a financial intermediary and to underwrite the shares pursuant to its commitment.
"The signature of that agreement with Kepler Cheuvreux, enables Theraclion to fund its development with flexibility. It will strengthen our cash perspective and improve visibility on our financing plan, and should gradually improve the liquidity of the shares" commented David Caumartin, Theraclion Chief Executive Officer.
For reference, should the entire line of financing be used, a shareholder currently holding 1.0% of the Company's share capital would see his/her ownership reduced to 0.90%[2].
This financing has been put in place pursuant to the twelfth resolution approved by the Shareholder Meeting held on March 31, 2014.
The number of shares issued and admitted for trading on Alternext in relation to this contract will be disclosed by means of Euronext notices and through the monthly statements related to the total number of voting rights and shares of the Company.
[1] Based on the closing price on March 17, 2015 (€10.72)
[2] Based on the number of Theraclion shares as of March 17, 2015 which is 3,776,503
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.
CEO Emmanuel Huynh / Sophie Boulila +33 (0)1 55 48 90 70 +33 (0)1 44 71 94 91 [email protected] [email protected]
Press Relations Thierry du Boislouveau Caroline Carmagnol / Valentine Boivin +33 (0)1 53 65 36 85 + 33 (0)1 44 54 36 63 [email protected] [email protected]
David Caumartin Financial Communications & Investors relations
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.